Showing results (121-130 of 179) with videos related to

Sort By:
Pageof 18
JAMA Oncology|May 1, 2020
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract CancerRichard D Kim, Vincent Chung, Olatunji B Alese, et al.
The Oncologist|July 15, 2020
Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal AdenocarcinomaHao Xie, Junjia Liu, Jun Yin, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 28, 2019
Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysisSiddhartha Yadav, Hao Xie, Irbaz Bin-Riaz, et al.
Targeted Oncology|September 2, 2022
Outcomes following FGFR Inhibitor Therapy in Patients with CholangiocarcinomaJennifer J Gile, Vanessa Wookey, Tyler J Zemla, et al.
Immunotherapy|September 7, 2018
Novel immunotherapy strategies for hepatobiliary cancersThomas T DeLeon, Yumei Zhou, Bolni M Nagalo, et al.
BJC Reports|January 14, 2025
A phase I study of the CDK4/6 inhibitor ribociclib combined with gemcitabine in patients with advanced solid tumorsAurora Norman, Mahesh Seetharam, Jacob Allred, et al.
Liver Cancer|May 11, 2026
Characterization of Patients with Unresectable Hepatocellular Carcinoma in REFLECT Who Achieved Tumor Response or Alpha-Fetoprotein Response When Treated with LenvatinibAmit Mahipal, Ann-Lii Cheng, Masatoshi Kudo, et al.
JCO Precision Oncology|February 1, 2022
Circulating Tumor DNA Profiling of Advanced Biliary Tract CancersKabir Mody, Pashtoon M Kasi, JuDong Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 19, 2020
Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal CancerRichard D Kim, Nilofer S Azad, Michael A Morse, et al.
JCO Precision Oncology|July 6, 2023
Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor EffectivenessJulia C F Quintanilha, Michael H Storandt, Ryon P Graf, et al.
Pageof 18